"Simvastatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.
| Descriptor ID |
D019821
|
| MeSH Number(s) |
D02.455.426.559.847.638.400.900 D04.615.638.400.900
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Simvastatin".
Below are MeSH descriptors whose meaning is more specific than "Simvastatin".
This graph shows the total number of publications written about "Simvastatin" by people in this website by year, and whether "Simvastatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 |
| 1998 | 4 | 0 | 4 |
| 1999 | 1 | 0 | 1 |
| 2000 | 6 | 1 | 7 |
| 2001 | 3 | 1 | 4 |
| 2002 | 1 | 2 | 3 |
| 2003 | 7 | 1 | 8 |
| 2004 | 1 | 1 | 2 |
| 2005 | 4 | 2 | 6 |
| 2006 | 4 | 2 | 6 |
| 2007 | 3 | 0 | 3 |
| 2008 | 8 | 3 | 11 |
| 2009 | 0 | 1 | 1 |
| 2010 | 3 | 2 | 5 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 3 | 1 | 4 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 2 | 1 | 3 |
| 2018 | 0 | 3 | 3 |
| 2019 | 0 | 2 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Simvastatin" by people in Profiles.
-
Simvastatin inhibits stem cell proliferation in human leiomyoma via TGF-ß3 and Wnt/ß-Catenin pathways. J Cell Mol Med. 2022 03; 26(5):1684-1698.
-
Simvastatin modulates estrogen signaling in uterine leiomyoma via regulating receptor palmitoylation, trafficking and degradation. Pharmacol Res. 2021 10; 172:105856.
-
Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy. J Clin Lipidol. 2019 Nov - Dec; 13(6):997-1007.e8.
-
Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 Disease. Stroke. 2019 03; 50(3):738-744.
-
Simvastatin and uterine fibroids: opportunity for a novel therapeutic option. Fertil Steril. 2018 12; 110(7):1272-1273.
-
Sphingolipids Signaling in Lamellipodia Formation and Enhancement of Endothelial Barrier Function. Curr Top Membr. 2018; 82:1-31.
-
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). Am J Cardiol. 2018 04 15; 121(8):940-948.
-
Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity. Genes Dev. 2017 07 01; 31(13):1339-1353.
-
No Effect of Omega-3 Carboxylic Acids on Pharmacokinetics/Pharmacodynamics of Warfarin or on Platelet Function When Co-administered with Acetylsalicylic Acid: Results of Two Phase I Studies in Healthy Volunteers. Am J Cardiovasc Drugs. 2017 Jun; 17(3):251-260.
-
Assessment of pharmacokinetic interaction between omega-3 carboxylic acids and the statins rosuvastatin and simvastatin: Results of 2 phase I studies in healthy volunteers. J Clin Lipidol. 2017 May - Jun; 11(3):739-748.